Home / Explore Insights / Clinical Outcomes of Remission Induction Therapy for Severe Antineutrophil Cytoplasmic Antibody Associated Vasculitis
/ Insights / Explore Insights / Clinical Outcomes Of Remission Induction Therapy For Severe Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Clinical Outcomes of Remission Induction Therapy for Severe Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CGM, St. Clair EW, Tchao NK, Viviano L, Ding L, Sejismundo LP, Mieras K, Ikle D, Jepson B, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH for the Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group
Arthritis & Rheumatism, 65: 2441. doi: 10.1002/art.38044 ‰ŰĘ
ITN
08/31/2013
Publication